“Evaluation of sphenopalatine ganglion blockade via intra oral route for the management of atypical trigeminal neuralgia” This article discusses use on an intraoral injection for treating Trigeminal neuralgia. I frequently utilize injection techniques for trigeminal neuralgia. My preferred injections are the intra-oral approach and the suprazygomatic approach because imaging is not necessary for accurate placemnt.
Injection offers the fastest relief for trigeminal neuralgia but my preferred method in self administration with cotton tipped nasal catheters that offer continual capillary feed of lidocaine to the sphenopalatine Ganglion. This method has been shown to be effective for migraines, cluster headaches, tension headaches, new daily persistent headache and well as post nasal surgery pain and trigeminal neuralgia.
More information is available at www.sphenopalatineganglionblocks.com.
Patient video testimonials are available at: https://www.youtube.com/channel/UCk9Bfz6pklC7_UluWFHzLrg/videos
Ira L Shapira DDS, D,ABDSM, D,AAPM, FICCMO
Chair, Alliance of TMD Organizations
Diplomat, American Academy of Pain Management
Diplomat, American Board of Dental Sleep Medicine
Regent & Fellow, International College of CranioMandibular Orthopedics
Board Eligible, American Academy of CranioFacial Pain
Dental Section Editor, Sleep & Health Journal
Member, American Equilibration Society
Member, Academy of Applied Myofunctional Sciences
Springerplus. 2016 Jun 27;5(1):906. doi: 10.1186/s40064-016-2612-8. eCollection 2016.
Evaluation of sphenopalatine ganglion blockade via intra oral route for the management of atypical trigeminal neuralgia.
Coven I1, Dayısoylu EH2.
The sphenopalatine ganglion (SPG) may be involved in persistent idiopathic facial pain and unilateral headaches. The role of SPG blockade via intra oral route in the management of trigeminal neuralgia (TN) is worthy of study.
In this retrospective study, patient records included patients with atypical TN (type 2) that persisted in spite of conservative treatment for at least 2 years, and an average pain intensity from the craniofacial region visual analogue scale (VAS) before examination. In group I the patients received carmapazepin 800 mg a day for at least 2 years. In group II 3 ml of local anesthetic agent consisting 2 ml bupivacaine and 1 ml prilocain in addition to 1 ml fentanyl, 0.5 ml betametasone disodium phosphate and 0.5 ml opaque was injected by the intraoral route. In this group, injection procedures were performed under local anesthesia with fluoroscopic guidance. The Kruskal-Wallis and Mann-Whitney U tests with Bonferroni correction were used for intergroup analysis. Age and sex differences were evaluated with one-way ANOVA and Fisher’s exact tests, respectively.
Significant differences were found between pre-op and 3rd day VAS values and also pre-op and 1st month VAS values. No significant differences were found between pre-op and 6th month VAS values.
The SPG blockade improves the quality of life of patients and a minimally-invasive procedure to management of TN, when compared to other methods.
PMID: 27386351 PMCID: PMC4923019 DOI: 10.1186/s40064-016-2612-8